Cuba’s Drug Shortage: Blockade Impact
- HAVANA (AP) — BioCubaFarma, the Cuban biopharmaceutical conglomerate, is actively pursuing strategic alliances to bolster its production capabilities.this initiative aims to identify new suppliers for the bio pharmaceutical...
- Mayda Mauri Pérez, president of BioCubaFarma, speaking at the XVI International Health Fair "Health for all," highlighted the importance of diversifying the company's supplier portfolio.
- “We are actively diversifying our industry's supplier network to secure choice options when acquiring raw materials, supplies, spare parts, equipment, and devices,” Pérez stated.
BioCubaFarma Seeks Strategic Alliances Amidst health Fair
Table of Contents
- BioCubaFarma Seeks Strategic Alliances Amidst health Fair
- BioCubaFarma: Your Questions Answered
- What is BioCubaFarma and What are its Goals?
- Why is BioCubaFarma Seeking New Suppliers?
- What Kind of Investors is BioCubaFarma Seeking?
- What Specific Projects is BioCubaFarma Highlighting?
- what is plasmapheresis?
- What are the Benefits of a Plasmapheresis Center?
- Why is Foreign Investment Being Sought for the Plasmapheresis Center?
- How does BioCubaFarma Collaborate with the Public Health System?
- Key Takeaways from BioCubaFarma’s initiatives
HAVANA (AP) — BioCubaFarma, the Cuban biopharmaceutical conglomerate, is actively pursuing strategic alliances to bolster its production capabilities.this initiative aims to identify new suppliers for the bio pharmaceutical industry, ensuring a consistent supply of essential resources.
Expanding Supplier Network
Mayda Mauri Pérez, president of BioCubaFarma, speaking at the XVI International Health Fair “Health for all,” highlighted the importance of diversifying the company’s supplier portfolio. The health fair, co-located with the V International Convention Cuba Health 2025, took place from April 21-24.
“We are actively diversifying our industry’s supplier network to secure choice options when acquiring raw materials, supplies, spare parts, equipment, and devices,” Pérez stated. This diversification is crucial to meeting the demand for medications and other inputs required by the national health system.
Seeking Investment for Innovative Projects
BioCubaFarma is also seeking investors, specifically those willing to take on risk, to co-develop innovative projects. These projects, while promising, require significant capital investment to reach the market.
Pérez emphasized the focus on therapies targeting prevalent diseases within the Cuban population, including oncological and neurodegenerative conditions. The company is actively seeking investors for these co-development proposals.
New Hemoderivatives Production Project
Pharmaceutical Laboratories AICA, a BioCubaFarma subsidiary, has presented a business proposal for constructing a plasmapheresis center.This center would be industry-managed, focusing on plasma extraction and subsequent marketing.
John Wilber Arrazcaeta, investment director at AICA, said the project is designed as a foreign investment opportunity. The initiative addresses the pharmaceutical industry’s challenges in obtaining sufficient plasma for producing hemoderivative products.
Arrazcaeta explained that the project aims for a different management approach to plasma acquisition. Unlike whole blood donation, plasmapheresis returns the red blood cell concentrate to the donor, retaining only the plasma.
the high costs associated with plasmapheresis kits and virus analysis of donors necessitate significant capital, with investment recovery planned through plasma sales, according to Arrazcaeta. The goal is to manage plasma acquisition differently and ensure marketable standards, possibly allowing for the extraction of other factors like coagulation elements.
Public Health Collaboration
Cuba stands out as one of the few nations where the biotechnology industry collaborates closely with the Public Health System to manage diseases that pose epidemiological risks.
BioCubaFarma: Your Questions Answered
What is BioCubaFarma and What are its Goals?
BioCubaFarma is the Cuban biopharmaceutical conglomerate, dedicated to enhancing cuba’s biopharmaceutical industry’s production capabilities. Its primary goal is to ensure a consistent supply of essential resources, especially for medications and other inputs required by the national health system. They are pursuing strategic alliances to meet this objective.
Why is BioCubaFarma Seeking New Suppliers?
BioCubaFarma is actively diversifying its supplier network to secure more options when acquiring crucial resources. These resources include raw materials, supplies, spare parts, equipment, and devices. this diversification is essential to ensure a reliable supply chain and meet the demand for medications and other inputs necessary for the national health system.
What Kind of Investors is BioCubaFarma Seeking?
BioCubaFarma is seeking investors who are willing to take on risk and co-develop innovative projects. These projects require significant capital investment to reach the market.the company is particularly interested in investors for projects related to therapies targeting prevalent diseases within the Cuban population, including oncological and neurodegenerative conditions.
What Specific Projects is BioCubaFarma Highlighting?
BioCubaFarma is highlighting a new hemoderivatives production project. Pharmaceutical Laboratories AICA, a BioCubaFarma subsidiary, has presented a business proposal for constructing an industry-managed plasmapheresis center. This center will focus on plasma extraction and subsequent marketing.
what is plasmapheresis?
Plasmapheresis is a medical procedure where plasma, the liquid part of blood, is separated from the blood cells. Unlike whole blood donation, plasmapheresis returns the red blood cell concentrate to the donor, retaining only the plasma.
What are the Benefits of a Plasmapheresis Center?
The aim is to manage plasma acquisition more efficiently and ensure marketable standards. It could also allow for the extraction of valuable components, such as coagulation elements. This project addresses the pharmaceutical industry’s need for sufficient plasma to produce hemoderivative products.
Why is Foreign Investment Being Sought for the Plasmapheresis Center?
john Wilber Arrazcaeta, investment director at AICA, stated that the project is designed as a foreign investment opportunity. The high costs associated with plasmapheresis kits and virus analysis of donors necessitate considerable capital. Investment recovery is planned through plasma sales.
How does BioCubaFarma Collaborate with the Public Health System?
Cuba’s biotechnology industry collaborates closely with the Public health System to manage diseases that pose epidemiological risks. This collaboration distinguishes Cuba as one of the few nations where such close ties exist between the biotechnology sector and public health.
Key Takeaways from BioCubaFarma’s initiatives
Here’s a summary of the key initiatives and their implications:
| Initiative | Description | Key Benefit |
| ——————————- | ——————————————————————————————————- | ——————————————————————————- |
| Supplier Network Diversification | Expanding the network to secure a consistent supply of raw materials, supplies, and equipment. | Ensures reliable production of medications and other essential healthcare inputs. |
| Investment in Innovative Projects | Seeking investors to co-develop therapies for prevalent diseases (oncological and neurodegenerative). | Introduces new treatments, improving patient outcomes. |
| Plasmapheresis Center | Establishing a center for plasma extraction and marketing managed by a BioCubaFarma subsidiary. | Addresses the need for plasma to produce hemoderivative products. |
| Public Health Collaboration | collaboration with Cuba’s Public Health System | Facilitating the management of diseases with epidemiological risks. |